Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy.
4 affiliations
- 1Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China.
- 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China. [email protected].
- 3Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China. [email protected].
- 4Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, 100142, China. [email protected].
Abstract
Background
Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in B-cell malignancies, but treatment response and immune-related toxicities remain heterogeneous. We characterized peri-infusion gut microbiome dynamics and examined their associations with subsequent response and toxicity.Methods
We performed shotgun metagenomic sequencing of 103 fecal samples from 21 patients with B-cell lymphoma collected on days -7, 0, 7, 14 and 28 relative to CAR-T infusion. We assessed pre-infusion stability, longitudinal microbiome remodeling, and associations with treatment response, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Longitudinal data were analyzed using mixed-effects models, and composition-aware sensitivity analyses incorporated centered log-ratio transformation and false-discovery-rate correction. Day -7 clinical and microbial features were also evaluated using exploratory nested cross-validation for response and CRS.Results
The gut microbiome remained broadly stable at the community level before infusion but underwent early, patient-specific remodeling after CAR-T therapy, characterized by a transient decline in alpha diversity and increased within-patient compositional deviation from baseline. Against this dynamic background, pre-infusion microbial variation was associated with subsequent clinical outcomes. Responders differed from non-responders in baseline microbial diversity, community structure and selected Sutterella and Segatella taxa. Patients who developed CRS showed lower microbial diversity and distinct community composition, whereas no comparable association was detected for ICANS. Exploratory nested cross-validation yielded AUCs of 0.51, 0.55 and 0.72 for the clinical, microbiome and combined response models, respectively, and 0.44, 0.85 and 0.83 for the corresponding CRS models.Conclusions
CAR-T therapy was accompanied by early, patient-specific gut microbiome remodeling, while pre-infusion microbial variation was associated with subsequent treatment response and CRS occurrence. These hypothesis-generating findings require confirmation in larger, independent prospective cohorts.
Related
- Fecal microbiome dynamics across reproductive stages in primiparous Świniarka sheep: a longitudinal study
- Longitudinal multi-omics analysis identify multi-kingdom microbiome-host interaction dynamics and diagnostic biomarkers of postoperative infection after kidney transplantation
- Longitudinal gut microbiome dynamics in neurosurgical ICU patients: Enterococcus expansion as a feature of microbial restructuring
- Gut microbiome composition and oxalate-related metabolic functions in staghorn calcium oxalate stone formers: a shotgun metagenomic analysis
- Circulating Histone Profiling in Acute Myeloid Leukaemia: Longitudinal Dynamics and Cross-Sectional Comparison with Myelodysplastic Neoplasms with Increased Blasts
BibTeX
@article{jia2026longitudinal,
title = {{Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy.}},
author = {Zimo Jia and Peixian Zheng and Haoxuan Zhang and Jiyue Zhang and Yiqin Lin and Jiajin Wu and Tao Pan and Yuqin Song and Weiping Liu and Meng Wu},
journal = {Journal of translational medicine},
year = {2026},
month = aug,
doi = {10.1186/s12967-026-08814-7},
url = {https://europepmc.org/article/MED/43009990},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Longitudinal metagenomic profiling of gut microbiome dynamics in B-cell lymphoma patients receiving CAR-T cell therapy.
AU - Zimo Jia
AU - Peixian Zheng
AU - Haoxuan Zhang
AU - Jiyue Zhang
AU - Yiqin Lin
AU - Jiajin Wu
AU - Tao Pan
AU - Yuqin Song
AU - Weiping Liu
AU - Meng Wu
PY - 2026
DA - 2026/08/14
JO - Journal of translational medicine
DO - 10.1186/s12967-026-08814-7
UR - https://europepmc.org/article/MED/43009990
AB - Background Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in B-cell malignancies, but treatment response and immune-related toxicities remain heterogeneous. We characterized peri-infusion gut microbiome dynamics and examined their associations with subsequent response and toxicity.Methods We performed shotgun metagenomic sequencing of 103 fecal samples from 21 patients with B-cell lymphoma collected on days -7, 0, 7, 14 and 28 relative to CAR-T infusion. We assessed pre-infusion stability, longitudinal microbiome remodeling, and associations with treatment response, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Longitudinal data were analyzed using mixed-effects models, and composition-aware sensitivity analyses incorporated centered log-ratio transformation and false-discovery-rate correction. Day -7 clinical and microbial features were also evaluated using exploratory nested cross-validation for response and CRS.Results The gut microbiome remained broadly stable at the community level before infusion but underwent early, patient-specific remodeling after CAR-T therapy, characterized by a transient decline in alpha diversity and increased within-patient compositional deviation from baseline. Against this dynamic background, pre-infusion microbial variation was associated with subsequent clinical outcomes. Responders differed from non-responders in baseline microbial diversity, community structure and selected Sutterella and Segatella taxa. Patients who developed CRS showed lower microbial diversity and distinct community composition, whereas no comparable association was detected for ICANS. Exploratory nested cross-validation yielded AUCs of 0.51, 0.55 and 0.72 for the clinical, microbiome and combined response models, respectively, and 0.44, 0.85 and 0.83 for the corresponding CRS models.Conclusions CAR-T therapy was accompanied by early, patient-specific gut microbiome remodeling, while pre-infusion microbial variation was associated with subsequent treatment response and CRS occurrence. These hypothesis-generating findings require confirmation in larger, independent prospective cohorts.
SN - 1479-5876
ER -